FDA
-
-
-
-
-
-
-
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
-
-
-
-
-
-
-
Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
-
-
-
-
-
-
-
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
Immuneering Corporation (IMRX) Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415
-
-
-
-
-
-
-
Immuneering Corporation (IMRX) Submits FDA IND Application for Phase 1/2a Trial of IMM-1-104
-
-
-
-
-
-
-
Immuneering Corporation (IMRX) Appoints Diana F. Hausman to its Board
-
330,004 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

